Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Noridza Rivera-Rodríguez
Observed names:
N Rivera-Rodriguez,
N. Rivera-Rodriguez,
N. Rivera‐Rodriguez,
Noridza Rivera-Rodriguez
Institutions:
University of Puerto Rico, Medical Sciences Campus,
University of Puerto Rico System
Observed institutions:
The University of Texas MD Anderson Cancer Center,
University of Puerto Rico, Medical Sciences Campus,
University of Puerto Rico System,
Moffitt Cancer Center,
Auxilio Mutuo Hospital
OpenAlex ID:
A5070504619
Recent advances in the management of mantle cell lymphoma
2013
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
·
Current Opinion in Oncology
·
7
Nitrofurantoin-induced microangiopathic haemolytic anaemia and thrombocytopaenia in a patient with systemic lupus erythematosus
2012
·
Linnette López-López
, Noridza Rivera-Rodríguez
, et al.
·
BMJ Case Reports
·
4
PDF
Abstract P3-14-17: Results of a novel neoadjuvant chemotherapy (NAC) for breast cancer
2013
·
N Rivera-Rodriguez
, F Cabanillas
, et al.
·
Cancer Research
·
2
OA13.03 RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC
2025
·
A.S. Mansfield
, E. Parent
, et al.
·
Journal of Thoracic Oncology
·
1
ABCL-1224: Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2025
·
Rakhee Vaidya
, Adelba Torres Lopez
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
625 | Outpatient Administration of Epcoritamab Monotherapy for Relapsed/refractory Diffuse Large B‐cell Lymphoma: Update From Epcore Nhl‐6
2025
·
R. Vaidya
, A. Torres Lopez
, et al.
·
Hematological Oncology
·
1
PDF
P1.13A.09 RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer
2024
·
S. Puri
, W. Akerley
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Results of a novel neoadjuvant chemotherapy (NAC) regimen for breast cancer.
2013
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
·
1
1062eP RYZ101 (225Ac-DOTATATE) + carboplatin + etoposide + atezolizumab in treatment-naïve patients with somatostatin receptor-expressing (SSTR2+) extensive-stage small-cell lung cancer (ES-SCLC)
2025
·
A.S. Mansfield
, E. Parent
, et al.
·
Annals of Oncology
POSTER: ABCL-1224 Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2025
·
Rakhee Vaidya
, Adelba Torres Lopez
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P2.16-03 RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer
2023
·
C. Mulvey
, R. Langdon
, et al.
·
Journal of Thoracic Oncology
PDF
Anaplastic Large Cell Lymphoma, ALK Positive, Presenting With Leukemic Phase: A Case Report
2018
·
Juan Carballo
, Roman Velez
, et al.
·
American Journal of Clinical Pathology
PDF
Epidemiologic findings of non-Hodgkin lymphoma (NHL) in Puerto Rico (PR).
2013
·
Jose Luis Ortega
, Maribel Tirado-Gomez
, et al.
·
Journal of Clinical Oncology
Results of upfront therapy for marginal zone lymphoma (MZL).
2013
·
Fernando Cabanillas
, Jose Luis Ortega
, et al.
·
Journal of Clinical Oncology
The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)
2012
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Blood
Absolute lymphocyte count (ALC), absolute monocyte count (AMC), and ALC/AMC ratio to predict outcome in aggressive non-Hodgkin lymphoma (aNHL).
2012
·
Noridza Rivera-Rodriguez
, Fernando Cabanillas
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
16
Citation count:
18
H-index:
2
I10-index:
Year
Topic
Type